Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses

Overview of attention for article published in Drug Design, Development and Therapy, November 2015

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 32 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 10 publications that cite this research output.

10

The most recent citing publications are shown below. View all 10 publications that cite this research output on Dimensions.

Nanoparticulate drugs and vaccines: Breakthroughs and bottlenecks of repurposing in breast cancer

Article in Journal of Controlled Release (August 2022)

The disruption of protein−protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition

Article in Acta Pharmaceutica Sinica B (November 2020)

The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir

Article in Cancers (November 2020)